MedTrace Logo

A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

NCT07667569 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-25

No results posted yet for this study

Summary

The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo.

The main question this clinical trial aims to answer is:

• Can ACT-777991 help return color to the skin of the face of adults with non-segmental vitiligo?

Researchers will compare ACT-777991 to placebo (a look-alike inactive treatment that contains no medicine) to see if ACT-777991 works to treat non-segmental vitiligo.

Trial participants will:

* Take the trial intervention (either ACT-777991 or placebo) daily for 24 weeks.
* Visit the clinic 7 times for check-up and tests.

Conditions

  • Non-Segmental Vitiligo

Interventions

DRUG

ACT-777991

ACT-777991 tablets

DRUG

Placebo

ACT-777991-matching placebo tablets

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Idorsia Pharmaceuticals Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-06-30
Completion
2027-07-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07667569 on ClinicalTrials.gov